NEW DELHI : The World Health Organization on Wednesday said that clinical trials of the repurposed anti-malaria drug hydroxychloroquine for treatment of covid-19 will resume, after a committee reviewed the available data for the drug. “On the basis of the available mortality data, the members of the committee recommended that there are no reasons to modify the trial protocol...
The Executive Group received this recommendation and endorsed continuation of all arms of the Solidarity Trial, including hydroxychloroquine," WHO director general Tedros Adhanom Ghebreyesus said at a virtual news briefing.
Ghebreyesus said that the Data Safety and Monitoring Committee, which had reviewed the data, will continue to closely monitor the safety of all